COEP Stock Performance, Insider Transaction and News

COEP - Bull Horn Holdings Corp.

Market Cap	61.14M	P/E	11.95	EPS this Y	-	Ern Qtrly Grth	-
Income	-21.27M	Forward P/E	-	EPS next Y	-	50D Avg Chg	19.00%
Sales	-	PEG	-	EPS past 5Y	-	200D Avg Chg	19.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	-	52W High Chg	-44.00%
Recommedations	2.00	Quick Ratio	0.51	Shares Outstanding	36.09M	52W Low Chg	83.00%
Insider Own	32.54%	ROA	-168.04%	Shares Float	20.21M	Beta	-0.89
Inst Own	13.27%	ROE	-485.13%	Shares Shorted/Prior	174.31K/39.72K	Price	11.95
Gross Margin	-	Profit Margin	-	Avg. Volume	25,647	Target Price	-
Oper. Margin	-	Earnings Date	-	Volume	1,176,367	Change	44.67%

Healthcare | Biotechnology | United States

About Bull Horn Holdings Corp.

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Bull Horn Holdings Corp. News

05/02/24	Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
04/02/24	Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award
02/26/24	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK
02/07/24	Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections
01/04/24	Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024
07:00 AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now
12/04/23	Coeptis Therapeutics to Present at the Emerging Growth Conference
10/31/23	Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023
10/24/23	Coeptis Therapeutics Announces $2 Million Private Placement
10/11/23	Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology
10/09/23	Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies
10/04/23	Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting
09/27/23	Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa
09/14/23	Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection
09/11/23	Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment
08/30/23	Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer
08/17/23	Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics
08/01/23	Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic
06/16/23	Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering
06/14/23	Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering

COEP Chatroom

AceFurley Posted - 2 days ago

$COEP

hnoversa Posted - 3 days ago

$COEP

Fallingknife Posted - 3 days ago

$COEP this company is an absolute joke. Sorry to say that but unfortunately it is true. They continue to trick investors with bullshit PR. The good thing is no one is buying it!!!!!!

Flowjob Posted - 3 days ago

$COEP a fluffy poster coming up lol Where is the data? Initial guidance was Q1 😂

Stock_Titan Posted - 3 days ago

$COEP Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting https://www.stocktitan.net/news/COEP/coeptis-therapeutics-announces-poster-data-presentation-at-american-lw3969ot40qn.html

Bone_In Posted - 04/30/24

$COEP it's starting to appear that this company is nothing but a vehicle to pay it's insiders extensive salaries off the backs of shareholders. They have been public going on 2 years and have provided absolutely 0 developments or increase in shareholder value. Not even a shareholder letter indicating updates or advances within the company. What a crock of shit. Just some random paid promo's for warrant holders to exit with some liquidity. Shameful.

AceFurley Posted - 04/30/24

$COEP At some point everyday this is the worst one on my list JFC! No volume for a while, I would anticipate some kind of move soon!?!

Jamestocksdn Posted - 04/25/24

$COEP R/S next

AceFurley Posted - 04/23/24

$COEP I got this, I'm gonna purchase 7 shares and see if that does anything!? NOPE huh

Fluteman_Greg Posted - 04/23/24

$COEP What is going on here? No news for over 2 months. How about some update on drug trials...Anything. Is anyone home in the starship? Investors getting impatient.

Bone_In Posted - 04/22/24

$COEP company appears to be full of shit

Bone_In Posted - 04/15/24

$COEP is that it? company needs to drop some real news and get this damn thing back up over a buck

Mayneverretire Posted - 04/15/24

$COEP Does nobody ever comment on here?

jercav2024 Posted - 04/11/24

$COEP got more watchers the $ELYM. Both gappers in the AM

FonsieTrader Posted - 04/11/24

$COEP Research and Analysis Paying Off! After diving deep into due diligence and technical analysis all day, the signs are clear: the price action and volume are speaking loud and clear! With insights pointing towards potential moves in the coming days, don't let this opportunity pass you by! Will you miss the train?

FonsieTrader Posted - 04/11/24

$COEP Massive volume alert! Price trading under more than 10x daily average volume screams opportunity. It's accumulation mode at its finest, offering a compelling risk-reward setup. Eyes peeled for potential gains!

FonsieTrader Posted - 04/11/24

Coeptis is collaborating with researchers from the University of Pittsburgh to develop licensed technology in the field of human treatment of cancer with antibody or antibody fragments using SNAP-CAR cell technology: bit.ly/49SOkqp $COEP

DaStockAnalyst_ Posted - 04/11/24

$COEP nice 0.4 hold

Bone_In Posted - 04/11/24

$COEP reversal confirmed? come on get back to the 70's!

DaStockAnalyst_ Posted - 04/11/24

$COEP looking for this to hold 0.4 and move up to 0.5

FonsieTrader Posted - 04/11/24

$COEP Opportunity knocking! Price pullback on very low volume to the Upper Bollinger Band Line signaling a prime entry point. With buying pressure holding strong, it's time to seize the moment!

VrtcIl Posted - 04/11/24

What are your targets on $COEP? Closest round level at 1. Take out profits right before those round numbers. Many orders on those levels are waiting to get filled. Price: 0.47 Float: 17.2M Short Float: 0.2 % 💰 Dollar Volume: 21.7K ℹ️ USA | Biotechnology

AintYoDaddy Posted - 04/11/24

$COEP nice 👍🏻

DaStockAnalyst_ Posted - 04/11/24

$COEP new high of the day... 17.95% up today!

FonsieTrader Posted - 04/11/24

$COEP HOD with volume above the average!! things are getting hot now

QUEFLO Posted - 04/11/24

$COEP will this hit a $1 ?

DaStockAnalyst_ Posted - 04/11/24

$COEP it broke and moving!!!!! lets go!

FonsieTrader Posted - 04/11/24

$RLYB already making moves as anticipated! Will $COEP be the next to shine? Keep an eye out – action is heating up

AintYoDaddy Posted - 04/11/24

$COEP yeahh, this is looking very good.

DaStockAnalyst_ Posted - 04/11/24

$COEP wants to breakout...... after breakout expecting some volume

Analyst Ratings

Ladenburg Thalmann	Buy	Sep 22, 23
EF Hutton	Buy	May 18, 23
EF Hutton	Buy	May 10, 23
JonesTrading	Buy	Apr 19, 23
EF Hutton	Buy	Apr 5, 23
EF Hutton	Buy	Mar 29, 23
EF Hutton	Buy	Dec 13, 22
EF Hutton	Buy	Dec 12, 22

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
Cogley Brian	Chief Financial Offi.. Chief Financial Officer	Jan 10	Buy	.67	5,000	3,350	30,000	01/17/24
DeSilva Tara	Director Director	Jan 12	Buy	0.57	2,266	1,292	32,266	01/16/24
Yerace Daniel Alexander	VP of Operations VP of Operations	Jan 05	Buy	.69	10,850	7,486	1,071,455	01/09/24
Salkind Gene	Director Director	Jan 05	Buy	.69	11,600	8,004	284,056	01/09/24
Mehalick David	CEO and President CEO and President	Jan 05	Buy	0.67	25,054	16,786	2,782,615	01/09/24
Harraden Circle Investments, L...	10% Owner 10% Owner	May 04	Sell	10.11	85,305	862,434	429,131	05/06/22